A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder

This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \[reduction in bingeing frequency\], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 weeks into the intervention, for treatment success after 8 weeks of the intervention.

NCT Number	NCT05664516
Lead Sponsor	Massachusetts General Hospital
Conditions	Binge-eating Disorder
Enrollment	60 participants
Start Date	2023-03-07
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-14